• Welcome!

    Learn about ARTIVeda for COVID-19.

    Learn more

  • Pipeline

    Review our self immunization protocol against cancers through our pipeline.

    Learn More

  • EdgePoint AI

    Introducing our revolutionary cluster-computer platform for AI processing.

    Learn more
123

Investor Relations

Press, quotes, SEC filings, alerts, more.

View Now

COVID-19

Launching ARTIVeda™ for COVID-19 in India.

Learn More

Pipeline

Cancer and viral infection treatment information.

Details

EdgePoint AI

Core cloud-computer AI platform.

Overview

Most recent news and events

Oncotelic Happenings

NUTRA Ingredients-Asia
Artemisinin for COVID-19: Indian and US firms launch clinically tested supplement after ayurvedic regulatory approval
Learn more >

CGTN America
Saran Saund, Chief Business Officer, and General Manager of the AI division, of Mateon-Oncotelic Therapeutics, talked about how India is using technology to fight COVID-19.
Watch the interview on Youtube HERE

Podcast
COVID-19 Therapy Based on AI Pharmaceutical Biotech and Ethnobotanicals with Dr. Saran Saund Oncotelic Therapeutics
Listen to the podcast HERE
Download the transcript HERE

Virtual Webinar
Ayurveda, Artemisia, and Covid-19
December 16, 2020 7AM PST – 10AM EST – 8:30PM IST
Featuring Global Experts in Ayurveda and Pharmacology.  Learn more >

Please Register HERE

The Zacks Small-Cap analyst

POSITIVE EARLY RESULTS FOR ARTIVEDATM IN TREATING COVID-19. Learn more >

Download this Report (PDF 480 KB)

Oncotelic and Windlas ARTIVeda announcement

Oncotelic and Windlas Biotech ready to launch ARTIVeda™ in India to address the COVID pandemic. Learn more >

11 Billion $

target markets

100 Plus

patent applications

2 Key

clinical programs

30 Years

experience

Questions or Comments?

Contact us
Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.